NEW YORK (GenomeWeb News) – BG Medicine today reported first quarter revenues of $888,000, up 85 percent from $480,000 in the first quarter of 2012.

The company also announced that it had appointed Paul Sohmer as president and CEO, replacing Eric Bouvier.

The revenue increase was driven by $820,000 in revenues from sales of the company's BGM Galectin-3 test, a 97 percent jump from the $416,000 it posted in Q1 2012. The remaining $68,000 in revenues came from BG's services business, up 6 percent from $64,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.